Pneumonia and Streptococcus pneumoniae vaccine

Andre G, Converso TR, Politano WR, Ferraz LF, Ribeiro ML, Leite LC, Darrieux M (2017) Role of Streptococcus pneumoniae proteins in evasion of complement-mediated immunity. Front Microbiol 8:224

Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS (2012) Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 67:540–545

Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375:1969–1987

Bogaert D, De Groot R, Hermans PW (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154

Briles DE, King JD, Gray MA, Mcdaniel LS, Swiatlo E, Benton KA (1996) PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 14:858–867

Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182:1694–1701

Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, Van Ginkel FW, Benjamin WH Jr (2003) Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188:339–348

Carvalho RP, Mesquita JS, Bonomo A, Elsas PX, Colombo AP (2009) Relationship of neutrophil phagocytosis and oxidative burst with the subgingival microbiota of generalized aggressive periodontitis. Oral Microbiol Immunol 24:124–132

CDC Symptoms and Complications (2017) Centers for Disease Control and Prevetion https://www.cdc.gov/pneumococcal/about/symptoms-complications.html . Accessed 10 Mar 2017

Choi SY, Tran TD, Briles DE, Rhee DK (2013) Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice. Clin Exp Vaccine Res 2:58–65

Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, Bentley SD, Hanage WP, Lipsitch M (2013) Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 45:656–663

Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK (2010) The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 78:2163–2172

ERS The burden of lung disease. European respiratory society (2017) http://www.erswhitebook.org/chapters/the-burden-of-lung-disease/ . Accessed 12 Mar 2017

Fedson DS, Guppy MJ (2013) Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 9:1382–1384

Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A (2006) Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 144:1–9

Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8:e1001017

French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF (2016) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. Malawi Med J 28:115–122

Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ (2005) Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 294:2712–2719

Gadsby NJ, Russell CD, Mchugh MP, Mark H, Conway Morris A, Laurenson IF, Hill AT, Templeton KE (2016) Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 62:817–823

Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, Lundberg U, Senn BM, Schunn M, Habel A, Henriques-Normark B, Ortqvist A, Kalin M, Von Gabain A, Nagy E (2008) Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 205:117–131

Glover DT, Hollingshead SK, Briles DE (2008) Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 76:2767–2776

Goldblatt D (2000) Conjugate vaccines. Clin Exp Immunol 119:1–3

Hayward S, Thompson LA, Mceachern A (2016) Is 13-valent pneumococcal conjugate vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23) superior to PPSV23 alone for reducing incidence or severity of pneumonia in older adults? A Clin-IQ. J Patient Cent Res Rev 3:111–115

Hirst RA, Kadioglu A, O’Callaghan C, Andrew PW (2004) The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 138:195–201

Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45–S53

Huss A, Scott P, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180:48–58

Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML, Neutra MR (2004) Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer’s patches. J Virol 78:947–957

Hvalbye BK, Aaberge IS, Lovik M, Haneberg B (1999) Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 67:4320–4325

Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA (2004) The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 39:1642–1650

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Mccullers JA, Pavia AT, Edwards KM, Finelli L (2015) Community-acquired pneumonia requiring hospitalization among U.S. Adults N Engl J Med 373:415–427

Johnstone J, Marrie TJ, Eurich DT, Majumdar SR (2007) Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 167:1938–1943

Johnstone J, Majumdar SR, Fox JD, Marrie TJ (2008) Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 134:1141–1148

Kadioglu A, Weiser JN, Paton JC, Andrew PW (2008) The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288–301

Kalin M (1998) Pneumococcal serotypes and their clinical relevance. Thorax 53:159–162

Kapatai G, Sheppard CL, Al-Shahib A, Litt DJ, Underwood AP, Harrison TG, Fry NK (2016) Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline. PeerJ 4:e2477

Kaplan SL, Mason EO Jr (1998) Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 11:628–644

Kim EH, Choi SY, Kwon MK, Tran TD, Park SS, Lee KJ, Bae SM, Briles DE, Rhee DK (2012) Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 30:2008–2019

Kim GL, Choi SY, Seon SH, Lee S, Park SS, Song JY, Briles DE, Rhee DK (2016) Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains. Vaccine 34:6481–6492

Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB (2017) Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older—United States, 2017. MMWR Morb Mortal Wkly Rep 66:136–138

Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T (2015) Intervals Between PCV13 and PPSV23 Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 64:944–947

Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Yamamoto M, Akiyoshi K, Kiyono H (2013) Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 81:1625–1634

Korsgaard J, Moller JK, Kilian M (2005) Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults. Int J Infect Dis 9:274–279

Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR (2002) Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169:566–574

Kraicer-Melamed H, O’donnell S, Quach C (2016) The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine 34:1540–1550

KSID (2014) Recommended immunization schedule for adults in Korea, by the Korean Society of Infectious Diseases, 2012. Clin Exp Vaccine Res 3:110–112

Lamm ME (1997) Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51:311–340

Lee H, Choi EH, Lee HJ (2014) Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 57:55–66

Levine MM, Dougan G (1998) Optimism over vaccines administered via mucosal surfaces. Lancet 351:1375–1376

Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R (2009) Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 77:2076–2083

Lu YJ, Leite L, Goncalves VM, Dias Wde O, Liberman C, Fratelli F, Alderson M, Tate A, Maisonneuve JF, Robertson G, Graca R, Sayeed S, Thompson CM, Anderson P, Malley R (2010) GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 28:7468–7475

Lynch JP, Zhanel GG (2009) Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 30:189–209

Mayoclinic Symptoms and causes, Pneumonia. Mayo Clinic (2017) http://www.mayoclinic.org/diseases-conditions/pneumonia/symptoms-causes/dxc-20204678 . Accessed 21 June 2017

Mcconnell MJ, Pachon J (2010) Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 29:1–5

Metzger DW, Furuya Y, Salmon SL, Roberts S, Sun K (2015) Limited efficacy of antibacterial vaccination against secondary serotype 3 pneumococcal pneumonia following influenza infection. J Infect Dis 212:445–452

Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila J, Leinonen M, Mccracken GH (2004) Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113:701–707

Mina MJ, Klugman KP (2013) Pathogen replication, host inflammation, and disease in the upper respiratory tract. Infect Immun 81:625–628

Minor PD (2015) Live attenuated vaccines: historical successes and current challenges. Virology 479–480:379–392

Moffitt KL, Yadav P, Weinberger DM, Anderson PW, Malley R (2012) Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine 30:4316–4322

Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, Maskin B, Bugna J, Rubinstein C, Aguilar L, Dalurzo L, Libster R, Savy V, Baumeister E, Aguilar L, Cabral G, Font J, Solari L, Weller KP, Johnson J, Echavarria M, Edwards KM, Chappell JD, Crowe JE, Williams JV, Melendi GA, Polack FP (2011) Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 17:U195–U225

Musher DM (2016) Editorial commentary: quantitative molecular approach to diagnosing pneumonia. Clin Infect Dis 62:824–825

Musher DM, Thorner AR (2014) Community-acquired pneumonia. N Engl J Med 371:1619–1628

Nascimento IP, Leite LC (2012) Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 45:1102–1111

Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–158

Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH (2011) Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29:5731–5739

Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC (2001) Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 69:5997–6003

Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I (2012) Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect Immun 80:461–468

Olarte L, Barson WJ, Barson RM, Romero JR, Bradley JS, Tan TQ, Givner LB, Hoffman JA, Lin PL, Hulten KG, Mason EO, Kaplan SL (2017) Pneumococcal Pneumonia Requiring Hospitalization in U.S. Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clin Infect Dis 64(12):1699–1704

Pavia AT (2013) What is the role of respiratory viruses in community-acquired pneumonia?: what is the best therapy for influenza and other viral causes of community-acquired pneumonia? Infect Dis Clin North Am 27:157–175

Picazo JJ (2009) Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Clin Microbiol Infect 15(Suppl 3):4–6

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201:32–41

Pliaka V, Kyriakopoulou Z, Markoulatos P (2012) Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 11:609–628

Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610–617

Robinson CL, Romero JR, Kempe A, Pellegrini C (2017) Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2017. MMWR Morb Mortal Wkly Rep 66:134–135

Roche AM, King SJ, Weiser JN (2007) Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 75:2469–2475

Sheng ZM, Chertow DS, Ambroggio X, Mccall S, Przygodzki RM, Cunningham RE, Maximova OA, Kash JC, Morens DM, Taubenberger JK (2011) Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci USA 108:16416–16421

Simon AK, Hollander GA, Mcmichael A (2015) Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 282:20143085

Song JY, Nahm MH, Moseley MA (2013) Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 28:4–15

Steel HC, Cockeran R, Anderson R, Feldman C (2013) Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediat Inflamm 2013:490346

Van Der Poll T, Opal SM (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374:1543–1556

Verhoeven D, Xu Q, Pichichero ME (2014) Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model. Vaccine 32:3205–3210

Vila-Corcoles A, Ochoa-Gondar O (2013) Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 30:263–276

WHO the top 10 causes of death, 2015 (2017a) World Health Organization. http://www.who.int/mediacentre/factsheets/fs310/en/index1.html . Accessed 12 Mar 2017

WHO causes of child mortality, 2015 (2017b) Global Health Observatory data World Health Organization. http://www.who.int/gho/child_health/mortality/causes/en/ . Accessed 12 Mar 2017

WHO pneumococcal disease (2017c) World Health Organization. http://www.who.int/ith/vaccines/pneumococcal/en/ . Accessed 12 Mar 2017

Wu K, Yao R, Wang H, Pang D, Liu Y, Xu H, Zhang S, Zhang X, Yin Y (2014) Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice. Vaccine 32:4179–4188

Wunderink RG, Waterer GW (2014) Community-acquired pneumonia. N Engl J Med 370:1863